AP2000001863A0 - Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion - Google Patents

Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Info

Publication number
AP2000001863A0
AP2000001863A0 AP2000001863A AP2000001863A AP2000001863A0 AP 2000001863 A0 AP2000001863 A0 AP 2000001863A0 AP 2000001863 A AP2000001863 A AP 2000001863A AP 2000001863 A AP2000001863 A AP 2000001863A AP 2000001863 A0 AP2000001863 A0 AP 2000001863A0
Authority
AP
ARIPO
Prior art keywords
inhibitors
cell adhesion
bone resorption
sulfonamide derivatives
novel sulfonamide
Prior art date
Application number
AP2000001863A
Other versions
AP1269A (en
Original Assignee
Aventis Pharma Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh, Genentech Inc filed Critical Aventis Pharma Gmbh
Publication of AP2000001863A0 publication Critical patent/AP2000001863A0/en
Application granted granted Critical
Publication of AP1269A publication Critical patent/AP1269A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/16Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
APAP/P/2000/001863A 1998-01-23 1999-01-16 Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. AP1269A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
PCT/EP1999/000242 WO1999037621A1 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Publications (2)

Publication Number Publication Date
AP2000001863A0 true AP2000001863A0 (en) 2000-09-30
AP1269A AP1269A (en) 2004-04-03

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001863A AP1269A (en) 1998-01-23 1999-01-16 Novel salfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion.

Country Status (25)

Country Link
EP (1) EP1049677A1 (en)
JP (1) JP2002501054A (en)
KR (1) KR20010034319A (en)
CN (1) CN1177832C (en)
AP (1) AP1269A (en)
AR (1) AR014456A1 (en)
AU (1) AU752882B2 (en)
BG (1) BG104630A (en)
BR (1) BR9907735A (en)
CA (1) CA2318221A1 (en)
EA (1) EA003102B1 (en)
HR (1) HRP20000493A2 (en)
HU (1) HUP0100520A3 (en)
ID (1) ID26219A (en)
IL (1) IL137423A0 (en)
NO (1) NO318795B1 (en)
NZ (1) NZ505613A (en)
PL (1) PL341871A1 (en)
SK (1) SK10632000A3 (en)
TR (1) TR200002160T2 (en)
TW (1) TWI247742B (en)
UA (1) UA63990C2 (en)
WO (1) WO1999037621A1 (en)
YU (1) YU47200A (en)
ZA (1) ZA99476B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521450A (en) * 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1070707A1 (en) * 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
FR2847254B1 (en) 2002-11-19 2005-01-28 Aventis Pharma Sa NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM
BRPI0509150B8 (en) * 2004-03-24 2021-05-25 Jerini Ag compounds for the inhibition of angiogenesis and the use of these
FR2870541B1 (en) * 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (en) * 2004-07-27 2006-11-17 Aventis Pharma Sa NEW GALENIC FORMULATIONS OF ACTIVE PRINCIPLES
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741796A (en) * 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (en) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス Bone formation promoter

Also Published As

Publication number Publication date
NO20003765L (en) 2000-09-25
NZ505613A (en) 2002-11-26
BR9907735A (en) 2000-10-17
EP1049677A1 (en) 2000-11-08
AU2518199A (en) 1999-08-09
EA003102B1 (en) 2002-12-26
IL137423A0 (en) 2001-07-24
BG104630A (en) 2001-04-30
TWI247742B (en) 2006-01-21
HUP0100520A3 (en) 2002-11-28
PL341871A1 (en) 2001-05-07
AU752882B2 (en) 2002-10-03
CN1293662A (en) 2001-05-02
HRP20000493A2 (en) 2001-06-30
ID26219A (en) 2000-12-07
SK10632000A3 (en) 2001-02-12
NO20003765D0 (en) 2000-07-21
AP1269A (en) 2004-04-03
ZA99476B (en) 1999-08-05
EA200000785A1 (en) 2001-02-26
JP2002501054A (en) 2002-01-15
YU47200A (en) 2002-11-15
UA63990C2 (en) 2004-02-16
WO1999037621A1 (en) 1999-07-29
NO318795B1 (en) 2005-05-09
CN1177832C (en) 2004-12-01
KR20010034319A (en) 2001-04-25
AR014456A1 (en) 2001-02-28
CA2318221A1 (en) 1999-07-29
HUP0100520A1 (en) 2001-07-30
TR200002160T2 (en) 2001-07-23

Similar Documents

Publication Publication Date Title
HUP0100520A3 (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
EP0998282A4 (en) Sulfonamides as cell adhesion inhibitors
PL339173A1 (en) Derivatives of benzamidine as inhibitors of factor xa
IL137385A0 (en) INHIBITORS OF α4 MEDIATED CELL ADHESION
EP1064391A4 (en) Antisense modulation of human mdm2 expression
AU4138599A (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
AU3359697A (en) Bone resorption inhibitors
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
AU2941997A (en) Novel imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
PL337645A1 (en) Novel amidine derivatives and their application as thrombosin inhibitors
AU7928898A (en) Determination of acoustic velocity in bone
PL341335A1 (en) Combination of ace and mmp inhibitors
AU6330199A (en) Electrochemical synthesis of perfluoroalkylfluorophosphoranes
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
PL343594A1 (en) Certain thiol inhibitors of endothelin-converting enzyme
PL342817A1 (en) Novel derivatives of dihydroxyhexanic acid
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU9312598A (en) Inhibitors of collagen assembly
AU2517399A (en) Utilization of substituted sulfonamides as antiviral agents and novel substances
HK1041270A1 (en) 2,-3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
AUPO907697A0 (en) Chemical supplementation of bone
AU1522400A (en) Substituted pyrimidine compositions and methods of use
ZA985218B (en) Novel sulfonamide inhibitors of farnesyl-protein transferase
PL352281A1 (en) Substituted derivatives of purine as inhibitors of adhesion of cells
AU5874800A (en) Antisense modulation of ets-2 expression